Publications

International multicenter investigation of LB20304, a new fluoronaphthyridone. by Hohl AF, Frei R, Punter V, von Graevenitz A, Knapp C, Washington J, Johnson D and Jones RN published in Clin. Microbiol. Infect. 1998; 4 (5): 280-284

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. by Biedenbach DJ, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 349-353

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. by Biedenbach DJ, Barrett MS, Croco MA, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 45-50

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 307-311

CQ-397 and CQ-414: Antimicrobial activity and spectrum of two fluoroquinolone—cephalosporin, dual-action compounds with carboxamido bonds. by Johnson DM and Jones RN. published in Clin. Microbiol. Infect. 1997; 3 (3): 335-344

Correlation of aztreonam susceptibility results obtained with the microscan system to reference tests: Reply. by Jones RN and Marshall SA published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 119-120

Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. by Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN and Saubolle MA published in J. Clin. Microbiol. 1997; 35 (8): 2115-2119

Cefotaxime in the treatment of prophylaxis of surgical infections. by Wittmann DH, Jones RN, Malledant J and Privitera G published in J. Chemother. 1997; 9 (Suppl 2): 19-33

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. by Cormican MG and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (1): 204-211

Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci. by Saraiva IH, Jones RN, Erwin M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (3): 217-222

Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 241-248

Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: Use of “direct” inoculation from Bactec 9240 blood culture bottles. by Putnam LR, Howard WJ, Pfaller MA, Koontz FP and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 101-104

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. by Biedenbach DJ, Schermer IH and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 1-5

Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 199-201

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1997; 35 (12): 3198-3202

Comparative evaluation of Etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria. by Marshall SA, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (3): 93-97

Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. by Marco F, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (1): 55-57

Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria. by Marco F, Barrett MS and Jones RN published in J. Antimicrob. Chemother. 1997; 40 (4): 605-607

Antimicrobial activity of RU-66647, a new ketolide. by Jones RN and Biedenbach DJ. published in Diagn. Microbiol. Infect. Dis. 1997; 27(1-2): 7-12

Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 21-28

A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. by Jones RN, Jacobs MR, Washington JA and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1997; 27 (3): 75-83

Critical evaluation of the Vitek GNS F6 card results compared to standardized, reference susceptibility test methods. by Jones RN, Marshall SA and Zerva L published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 35-40

Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results. by Jones RN, Barrett MS and Deguchi T published in Diagn. Microbiol. Infect. Dis. 1997; 28 (4): 193-200

Ofloxacin otic solution for treatment of otitis externa in children and adults. by Jones RN, Milazzo J and Seidlin M published in Arch. Otolaryngol. Head Neck Surg. 1997; 123 (11): 1193-1200

Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric Gram- negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. by Jones RN, Pfaller MA, Marshall SA, Hollis RJ and Wilke WW published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 187-192

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 113-116

Proposed MIC quality control guidelines for National Committee for Clinical Laboratory Standards susceptibility tests using seven veterinary antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin G-novobiocin, pirlimycin, premafloxacin, and spectinomycin. by Marshall SA, Jones RN, Wanger A, Washington JA, Doern GV, Leber AL and Haugen TH published in J. Clin. Microbiol. 1996; 34 (8): 2027-2029

Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U- 100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. by Worth S, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 87-91

Critical appraisal of Etest for the detection of fluoroquinolone resistance. by Jones RN, Erwin ME and Croco JL published in J. Antimicrob. Chemother. 1996; 38 (1): 21-25

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (4): 153-161

Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System. by Doern GV, Torres BB, Jankins M and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (3): 133-135

False resistance to metronidazole by Etest among anaerobic bacteria investigations of contributing test conditions and medium quality. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 117-119

Phenotypic detection of mecA-positive staphylococcal bloodstream isolates: High accuracy of simple disk diffusion tests. by Cormican MG, Wilke WW, Barrett MS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (3): 107-112

Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the Etest ESBL screen. by Cormican MG, Marshall SA and Jones RN published in J. Clin. Microbiol. 1996; 34 (8): 1880-1884

Re-evaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. by Cormican MG, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 1996; 1 (3): 190-194

Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1996; 34 (12): 3214-3217

Evaluation of Vitek and API 20S for species identification of enterococci. by Sader HS, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (4): 315-319

Evaluation of S1 chromogenic cephalosporin β-lactamase disk assay tested against Gram-positive anaerobes, coagulase-negative staphylococci, Prevotella spp. and Enterococcus spp. by Marshall SA, Sutton LD and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (4): 353-355

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres. by Jones RN, Kehrberg EN and Erwin ME published in Drugs 1995; 49 (Suppl 2): 179-181

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the Etest to recognize glycopeptide-resistant strains. by Jones RN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 95-100

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A review. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (1-2): 19-33

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. by Jones RN published in J. Chemother. 1995; 7 (Suppl 2): 7-16

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1. by Doern GV, Jones RN, Gerlach EH, Washington JA, Biedenbach DJ, Brueggemann A, Erwin ME, Knapp C and Raymond J published in J. Clin. Microbiol. 1995; 33 (6): 1665-1667

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). by Cormican MG, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 51-54

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates. by Cormican MG and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (4): 227-230

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 57-60

Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. by Murphy SP, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 20 (1): 49-55

Interpretive criteria for DU-6859a disk diffusion tests using 5- micrograms disks. by Jones RN, Johnson DM and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 18 (2): 125-127

Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. by Jones RN, Doern GV, Gerlach EH, Hindler J and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 18 (4): 243-249

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group. by Jones RN, Sader HS and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 20 (2): 93-98